TP53 and cancer: Alteration of the p53 pathway is an almost universal hallmark of human cancers, with 22 million cancer patients living with abrogation of the p53 pathway, half of which display suppressed p53 function (Brown et al., 2009) and half of which exhibit p53 mutations.